Brief: Advicenne Wins UK Approval To Market Sibnayal For dRTA
02/07/2021 06:04
July 2 (Reuters) - Advicenne SA ADVIC.PA :
* ADVICENNE RECEIVES MHRA APPROVAL TO MARKET SIBNAYAL™
(ADV7103)
IN THE UK FOR THE TREATMENT OF DRTA
Source text for Eikon: ID:nGNE5wnfdK
Further company coverage: ADVIC.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Advicenne SA
See all newsBrief: Advicenne Secures Cash Runway To Q2 2027 Through Bond Financing Of Amount Of Up To €3.8 Mln
Corrected: BRIEF-Advicenne FY Net Income EUR -9.532 Million (March 26)
France's Advicenne 2025 sales rise, net loss widens
Brief: Advicenne FY Net Income EUR -9.532 Million
Brief: Advicenne SA -Cash Position Of EUR 2.0 Million With Unchanged Financial Visibility In Q1 2025